Академический Документы
Профессиональный Документы
Культура Документы
ster-
man J: Residual insulin production, glycaemic control and prevalence of
microvascular lesions and polyneuropathy in long-term type 1 (insulin-
dependent) diabetes mellitus. Diabetologia 30:208213, 1987
46. Ludvigsson J, Heding LG, Larsson Y, Leander E: C-peptide in juvenile
diabetics beyond the postinitial remission period. Acta Pdiatr Scand
66:177184, 1977
47. Madsbad S, McNair P, Faber OK, Binder C, Christiansen C, Transbl I:
-Cell function and metabolic control in insulin treated diabetics. Acta
Endocrinologica 93:196200, 1980
48. Sjo berg S, Gjo tterberg M, Berglund L, Mo ller E, O
sterman J: Residual
C-peptide excretion is associated with a better long-term glycemic
control and slower progress of retinopathy in type 1 (insulin-dependent)
diabetes mellitus. J Diabet Complications 1:1822, 1991
49. Grajwer LA, Pildes RS, Horwitz DL, Rubenstein AH: Control of juvenile
diabetes mellitus and its relationship to endogenous insulin secretion as
measured by C-peptide immunoreactivity. J Pediatr 90:4248, 1977
50. Gonen B, Goldman J, Baldwin D, Goldberg RB, Ryan WG, Blix PM,
Schanzlin D, Fritz KJ, Rubenstein AH: Metabolic control in diabetic
patients: effect of insulin-secretory reserve (measured by plasma C-
peptide levels) and circulating insulin antibodies. Diabetes 28:749753,
1979
51. Fukuda M, Tanaka A, Tahara Y, Ikegami H, Yamamoto Y, Kumahara Y,
Shima K: Correlation between minimal secretory capacity of pancreatic
-cells and stability of diabetic control. Diabetes 37:8188, 1988
52. Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T,
Wahren J: Benecial effects of C-peptide on incipient nephropathy and
neuropathy in patients with type 1 diabetes mellitus. Diabet Med 17:181
189, 2000
53. The DCCT Research Group: Effects of age, duration and treatment of
insulin-dependent diabetes mellitus on residual beta-cell function: obser-
vations during eligibility testing for the Diabetes Control and Complica-
tions Trial (DCCT). J Clin Endocrinol Metab 65:3036, 1987
54. Steffes MW, Sibley S, Jackson M, Thomas W: -Cell function and the
development of diabetes-related complications in the Diabetes Control
and Complications Trial. Diabetes Care 26:832836, 2003
55. Hamilton DV, Mundia SS, Lister J: Mode of presentation of juvenile
diabetes. Br Med J 2:211212, 1976
56. Pinkey JH, Bingley PJ, Sawtell PA, Dunger DB, Gale EA: Presentation and
progress of childhood diabetes mellitus: a prospective population-based
study: The Barts-Oxford Study Group. Diabetologia 37:7074, 1994
57. Pozzilli P, Visalli N, Buzzetti R, IMDIAB Group: Metabolic and immune
parameters at clinical onset of insulin-dependent diabetes: a population
based study. Metabolism 47:12051210, 1998
58. Knip M, Ilonen J, Mustonen A, Akerblom HK: Evidence of an accelerated
B-cell destruction in HLA-Dw3/Dw4. Diabetologia 29:347, 1986
59. Snorgaard O, Larsen LH, Binder C: Homogeneity in pattern of decline of
-cell function in IDDM. Diabetes Care 15:10091015, 1992
60. Pozzilli P, Mesturino C, Crino` A, Gross T, Jeng L, Visalli N, IMDIAB
Group: Is the process of beta cell destruction in type 1 diabetes at time of
diagnosis more extensive in females than in males? European J Endoc
145:15, 2001
61. Shah SC, Malone JI, Simpson NE: A randomized trial of intensive insulin
therapy in newly diagnosed insulin-dependent diabetes. New Engl J Med
350:550555, 1989
62. Pozzilli P, Browne P, Kolb H: Meta-analysis of nicotinamide treatment in
patients with recent-onset IDDM: the Nicotinamide Trialists. Diabetes
Care 19:13571363, 1996
63. Pozzilli P, Maclaren NK: Immunotherapy at clinical diagnosis of insulin
dependent diabetes: an approach still worth considering. Trends Endo-
crinol Metab 4:101105, 1993
64. Skyler JS, Marks JB: Immune intervention in type 1 diabetes mellitus.
Diabetes Rev 1:1542, 1993
65. Abiru N, Takino H, Yano M, Kawasaki E, Yamasaki H, Yamaguchi Y,
Akazawa S, Nagataki S: Clinical evaluation of non-insulin-dependent
diabetes mellitus patients with autoantibodies to glutamic acid decarbox-
ylase. J Autoimmun 9:683688, 1996
66. Carlsson A, Sundkvist G, Groop L, Tuomi T: Insulin and glucagon
secretion in patients with slowly progressing autoimmune diabetes
(LADA). J Clin Endocrinol Metab 85:7680, 2000
67. Desailloud R, Fajardy I, Vambergue A, Prevost G, Pigny P, Fontaine P:
Autoimmune markers in slow type 1 diabetes: confrontation to type 1
diabetes. Diabetes Metab 26:353360, 2000
68. Falorni A, Gambelunghe G, Forini F, Kassi G, Cosentino A, Candeloro P,
Bolli GB, Brunetti P, Calcinaro F: Autoantibody recognition of COOH-
terminal epitopes of GAD65 marks the risk for insulin requirement in
adult-onset diabetes mellitus. J Clin Endocrinol Metab 85:309316, 2000
69. Fukui M, Nakano K, Shigeta H, Yoshimori K, Fujii M, Kitagawa Y, Mori H,
Kajiyama S, Nakamura N, Abe N, Obayashi H, Fukui I, Ohta K, Ohta M,
Kondo M: Antibodies to glutamic acid decarboxylase in Japanese diabetic
patients with secondary failure of oral hypoglycaemic therapy. Diabetic
Med 14:148152, 1997
70. Gambelunghe G, Forini F, Laureti S, Murdolo G, Toraldo G, Santeusanio
F, Brunetti P, Sanjeevi CB, Falorni A: Increased risk for endocrine
autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibod-
ies. Clin Endocrinol 52:565573, 2000
71. Goetz FC, Roel J, Jacobs DR Jr, Barbosa J, Hannan P, Palmer J, Hagopian
W: Declining beta-cell function in type 2 diabetes: 5-year follow-up and
immunologic studies of the population of Wadena, MN. Metabolism
51:144148, 2002
72. Gottsa ter A, Landin-Olsson M, Fernlund P, Lernmark , Sundkvist G:
-Cell function in relation to islet cell antibodies during the rst 3 yr after
clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care
16:902910, 1993
73. Gottsa ter A, Landin-Olsson M, Lernmark , Fernlund P, Sundkvist G,
Hagopian WA: Glutamate decarboxylase antibody levels predict rate of
-Cell decline in adult-onset diabetes. Diabetes Res Clin Pract 27:133
140, 1995
74. Gray RS, Irvine WJ, Cameron EH, Duncan LJ: Glucose and insulin
responses to oral glucose in overt non-insulin-dependent diabetics with
and without the islet cell antibody. Diabetes 29:312316, 1980
75. Groop LC, Bottazzo GF, Doniach D: Islet cell antibodies identify latent
type 1 diabetes in patients aged 3575 years at diagnosis. Diabetes
35:237241, 1986
76. Hosszufalusi N, Vatay A, Rajczy K, Prohaszka Z, Pozsonyi E, Horvath L,
Grosz A, Gero L, Madacsy L, Romics L, Karadi I, Fust G, Panczel P: Similar
genetic features and different islet cell autoantibody pattern of latent
autoimmune diabetes in adults (LADA) compared with adult-onset type 1
diabetes with rapid progression. Diabetes Care 26:452457, 2003
77. Inukai T, Fujiwara Y, Tayama K, Aso Y, Ogino K, Takemura Y: Clinical
characteristics of patients with the initial diagnosis of NIDDM with
positivity for antibodies to glutamic acid dicarboxylase. Exp Clin Endo-
crinol Diabetes 105:327330, 1997
78. Isomaa B, Almgren P, Henricsson M, Taskinen M-R, Tuomi T, Groop LC,
Sarelin L: Chronic complications in patients with slowly progressing
autoimmune type 1 diabetes (LADA). Diabetes Care 22:13471353, 1999
79. Kasuga A, Maruyama T, Ozawa Y, Takei I, Falorni A, Lernmark , Saruta
T: Antibody to the M(r) 65,000 isoform of glutamic acid decarboxylase are
J.P. PALMER AND ASSOCIATES
DIABETES, VOL. 53, JANUARY 2004 263
detected in non-insulin-dependent diabetes in Japanese. J Autoimmun
9:105111, 1996
80. Kobayashi T, Nakanishi K, Sugimoto T, Itoh T, Murase T, Kosaka K, Tsuji
K: Maleness as risk factor for slowly progressive IDDM. Diabetes Care
12:711, 1989
81. Kobayashi T, Nakanishi K, Murase T, Kosaka K: Small doses of subcuta-
neous insulin as a strategy for preventing slowly progressive -cell failure
in islet cell antibodypositive patients with clinical features of NIDDM.
Diabetes 45:622626, 1996
82. Kobayashi T, Itoh T, Kosaka K, Sato K, Tsuji K: Time course of islet cell
antibodies and beta-cell function in non-insulin-dependent stage of type I
diabetes. Diabetes 36:510517, 1987
83. Landin-Olsson M: Latent autoimmune diabetes in adults. Ann N Y Acad
Sci 958:112116, 2002
84. Maruyama T, Kasuga A, Ozawa Y, Nagata A, Abiko F, Suzuki Y, Saruta T:
Glutamic acid decarboxylase 65 (GAD65) antibodies and insulin autoan-
tibodies in Japanese patients with non-insulin-dependent diabetes melli-
tus. Endocr J 44:4351, 1997
85. Niskanen LK, Tuomi T, Karjalainen J, Groop LC, Uusitupa MIJ: GAD
antibodies in NIDDM: ten-year follow-up from the diagnosis. Diabetes
Care 18:15571565, 1995
86. Pietropaolo M, Barinas-Mitchell E, Pietropaolo SL, Kuller LH, Trucco M:
Evidence of islet cell autoimmunity in elderly patients with type 2
diabetes. Diabetes 49:3238, 2000
87. Rattarasarn C, Aguilar Diosdado M, Soonthornpun S: Glutamic acid
decarboxylase antibodies in non-insulin-dependent diabetes patients with
secondary sulfonylurea failure in Thailand. Diabetes Res Clin Pract
37:193197, 1997
88. Takino H, Yamasaki H, Sera Y, Abe T, Ozaki M, Kondo H, Sakamaki H,
Kawasaki E, Yamaguchi Y, Nagataki S, Eguchi K: The preliminary report
from the nation-wide prevention study for type 1 diabetes initially
diagnosed as type 2 in Japan. Diabetes Metab Rev 14:334335, 1998
89. To rn C, Landin-Olsson M, O